New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
04:55 EDTACRX, ACRX, BLRX, BLRX, CRIS, CRIS, NEO, NEO, PRTA, PRTA, PTCT, PTCT, LGND, LGND, GALE, GALE, IPCI, IPCIRoth Capital to hold a conference
ROTH Healthcare Corporate Access Day to be held in London, England on June 23-24.
News For ACRX;BLRX;CRIS;NEO;PRTA;PTCT;LGND;GALE;IPCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:56 EDTACRXAcelRx management to meet with BofA/Merrill
Meeting to be held in New York on October 29 hosted by BofA/Merrill.
October 23, 2014
09:23 EDTLGNDLigand price target raised to $121.50 from $92 at Roth Capital
Subscribe for More Information
October 22, 2014
17:19 EDTIPCIIntellipharmaceutics reports positive results from Regabatin phase 1 trials
Intellipharmaceutics provided an update on the progress of its Regabatin XR product development. Regabatin XR pregabalin extended release capsules are the company's non-generic pregabalin formulations. The company has recently conducted and analyzed the results of six phase I clinical trials involving a twice-a-day formulation and a once-a-day formulation. For formulations directed to certain indications which include fibromyalgia, the results suggested that Regabatin XR 82.5 mg twice-a-day, or BID, dosage was comparable in bioavailability to Lyrica 50 mg three-times-a-day, or TID, dosage. For formulations directed to certain other indications which include neuropathic pain associated with diabetic peripheral neuropathy, the results suggested that Regabatin XR 165 mg once-a-day dosage was comparable in bioavailability to Lyrica 75 mg BID dosage. Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury and fibromyalgia. A controlled-release version of pregabalin should reduce the number of doses patients take, which could improve patient compliance, and therefore possibly enhance clinical outcomes. Plans are underway to initiate an investigational new drug application under the new drug application 505b2 regulatory pathway with the FDA, with a view to possible commercialization in the U.S. following the Dec. 30, 2018 expiry of the patent covering the pregabalin molecule.
14:08 EDTGALEGalena files to sell 2M shares of common stock for holders
Subscribe for More Information
07:19 EDTACRXAcelRx's Zalviso for abdominal pain shows positive Phase 3 results
Subscribe for More Information
October 16, 2014
07:02 EDTACRXAcelRx updates patent portfolio for Zalviso and platform technologies
Subscribe for More Information
October 15, 2014
16:47 EDTIPCIIntellipharmaceutics reports Q3 EPS (7c), consensus (11c)
Reports Q3 revenue $1.1M, consensus $800K.
October 14, 2014
07:17 EDTGALEGalena receives notice of allowance of improvement patent for NeuVax in Japan
Galena Biopharma announced the notice of allowance from the Japanese Patent Office for NeuVax covering the use of NeuVax alone or in combination with other agents to prevent recurrence of any HER2/neu expressing breast cancer tumor having an immunohistochemistry level of 1+ or 2+, or a fluorescence in situ hybridization rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent will expire in 2027, not including any patent term extensions.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use